Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.64 |
| ▸ | TTPA | P49638 | 1/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | PDE4A | P27815 | 1/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.63 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.59 |
| ▸ | GSTO1 | P78417 | 2/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | AKT1 | P31749 | 3/20 | 0.58 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.58 |
| ▸ | PHLPP1 | O60346 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL39202 | 0.95 | LMNA (0.71) | LMNAMAPTMEN1KMT2AGSTP1 | |
| SCHEMBL17874902 | 0.95 | LMNA (0.71) | LMNAMAPTMEN1KMT2AGSTP1 | |
| SCHEMBL3460249 | 0.95 | LMNA (0.71) | LMNAMAPTMEN1KMT2AGSTP1 | |
| SCHEMBL14695837 | 0.95 | LMNA (0.71) | LMNAMAPTMEN1KMT2AGSTP1 | |
| SCHEMBL2695150 | 0.95 | LMNA (0.71) | LMNAMAPTMEN1KMT2AGSTP1 | |
| Succinic Acid SCHEMBL705370 | 0.94 | GSTO1 (0.67) | LMNAMAPTMEN1KMT2AGSTP1 | |
| Phosphoric Acid SCHEMBL8652705 | 0.92 | GSTO1 (0.65) | LMNAMAPTMEN1KMT2AGSTP1 | |
| Phosphoric Acid SCHEMBL20917308 | 0.92 | GSTO1 (0.65) | LMNAMAPTMEN1KMT2AGSTP1 | |
| Alcohol SCHEMBL28691903 | 0.92 | LMNA (0.67) | LMNAMAPTMEN1KMT2AGSTP1 | |
| Benzoquinone SCHEMBL1187748 | 0.91 | LMNA (0.63) | LMNAMAPTMEN1KMT2AGSTP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118524840-A | EPA-EE nano lipid composition, preparation method and application thereof | 中国科学院上海药物研究所 | 2024-08-20 | — | — | CN | claimed |
| CN-110669255-A | Stabilizer compositions containing substituted chroman compounds and methods of use thereof | 塞特克技术公司 | 2020-01-10 | — | — | CN | claimed |
| US-9801913-B2 | Barrier layer | ATRIUM MEDICAL CORPORATION (US) | 2017-10-31 | — | — | US | claimed |
| US-8795703-B2 | Stand-alone film and methods for making the same | ATRIUM MEDICAL CORPORATION (US) | 2014-08-05 | — | — | US | claimed |
| US-8367099-B2 | Perforated fatty acid films | ATRIUM MEDICAL CORPORATION (US) | 2013-02-05 | — | — | US | claimed |
| WO-2010104786-A1 | USE OF CRYOGENIC PROCESSING TO OBTAIN A SUBSTANTIALLY-THICKENED FORMULATION | ATRIUM MEDICAL CORPORATION (US) | 2010-09-16 | — | — | WO | claimed |
| US-20100233231-A1 | USE OF CRYOGENIC PROCESSING TO OBTAIN A SUBSTANTIALLY-THICKENED FORMULATION | ATRIUM MEDICAL CORPORATION | 2010-09-16 | — | — | US | claimed |
| EP-2086605-A2 | PERFORATED BIOABSORBABLE OIL FILM AND METHODS FOR MAKING THE SAME | Atrium Medical Corporation (US) | 2009-08-12 | — | — | EP | claimed |
| WO-2008039308-A2 | PERFORATED BIOABSORBABLE OIL FILM AND METHODS FOR MAKING THE SAME | ATRIUM MEDICAL CORPORATION (US) | 2008-04-03 | — | — | WO | claimed |
| EP-1812022-A2 | STAND-ALONE FILM AND METHODS FOR MAKING THE SAME | Atrium Medical Corporation (US) | 2007-08-01 | — | — | EP | claimed |
| US-20070071798-A1 | Perforated bioabsorbable oil film and methods for making the same | ATRIUM MEDICAL CORPORATION (US) | 2007-03-29 | — | — | US | claimed |
| US-20060088596-A1 | Solubilizing a drug for use in a coating | ATRIUM MEDICAL CORPORATION (US) | 2006-04-27 | — | — | US | claimed |
| US-20060083768-A1 | Method of thickening a coating using a drug | ATRIUM MEDICAL CORPORATION (US) | 2006-04-20 | — | — | US | claimed |
| WO-2006036984-A2 | STAND-ALONE FILM AND METHODS FOR MAKING THE SAME | ATRIUM MEDICAL CORPORATION (US) | 2006-04-06 | — | — | WO | claimed |
| WO-2006036970-A2 | METHOD OF THICKENING A COATING USING A DRUG | ATRIUM MEDICAL CORPORATION (US) | 2006-04-06 | — | — | WO | claimed |
| WO-2006036967-A1 | SOLUBILIZING A DRUG FOR USE IN A COATING | ATRIUM MEDICAL CORPORATION (US) | 2006-04-06 | — | — | WO | claimed |
| US-20060067983-A1 | Stand-alone film and methods for making the same | ATRIUM MEDICAL CORPORATION (US) | 2006-03-30 | — | — | US | claimed |
| WO-2023126026-A9 | EPA-EE LIPID NANOCOMPOSITE, FORMULATION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 中国科学院上海药物研究所 | 2024-09-12 | — | — | WO | disclosed |
| US-20060067976-A1 | Formation of barrier layer | ATRIUM MEDICAL CORPORATION (US) | 2006-03-30 | — | — | US | disclosed |
| US-20060067975-A1 | UV cured gel and method of making | ATRIUM MEDICAL CORPORATION (US) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060067975-A1 | UV cured gel and method of making | PTGES, PTGES2, ALOX5 | LMNA 755/4885MAPT 1265/4885MEN1 4405/4885 |
| US-20100233231-A1 | USE OF CRYOGENIC PROCESSING TO OBTAIN A SUBSTANTIALLY-THICKENED FORMULATION | LIPA, CETP, CPT2 | LMNA 112/4885MAPT 75/4885MEN1 2327/4885 |
| US-20060083768-A1 | Method of thickening a coating using a drug | ABCB1, SLC10A2, ABCB11 | LMNA 2291/4885MAPT 531/4885MEN1 700/4885 |
| US-20060088596-A1 | Solubilizing a drug for use in a coating | ABCB11, ABCB1, SLC10A2 | LMNA 3220/4885MAPT 1278/4885MEN1 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.